Described herein are .sup.9-THC prodrugs, methods of making .sup.9-THC prodrugs, formulations comprising .sup.9-THC prodrugs and methods of using .sup.9-THC. One embodiment described herein relates to the transdermal administration of a .sup.9-THC prodrug for treating and preventing diseases and/or disorders.

To improve the emission efficiency, the driving voltage and the lifetime of an organic light-emitting device using a delayed fluorescent material. A host material for a delayed fluorescent material, containing a compound represented by the following general formula: R.sup.1 to R.sup.5 each are a substituent not containing a cyano group, n1 to n5 each are 0 to 4, Ar is a monocyclic arylene group or a monocyclic heteroarylene group.

##STR00001##

An acid diffusion control agent includes a compound represented by a formula (1), a compound represented by a formula (2) or both thereof. R.sup.1 represents a hydrocarbon group comprising a monovalent alicyclic structure, or the like. R.sup.2 and R.sup.3 each independently represent a monovalent hydrocarbon group, or the like. R.sup.4 and R.sup.5 each independently represent a monovalent hydrocarbon group, or the like. R.sup.6 and R.sup.7 each independently represent a monovalent hydrocarbon group, or the like. R.sup.8 represents a monocyclic heterocyclic group together with the ester group and with the carbon atom. n is an integer of 1 to 6. R.sup.9 represents a monovalent hydrocarbon group, or the like. R.sup.10 represents a monovalent hydrocarbon group having 1 to 10 carbon atoms. R.sup.11 and R.sup.12 each independently represent a monovalent hydrocarbon group, or the like. R.sup.13 and R.sup.14 each independently represent a monovalent hydrocarbon group, or the like.

##STR00001##

Described herein are .sup.9-THC prodrugs, methods of making .sup.9-THC prodrugs, formulations comprising .sup.9-THC prodrugs and methods of using .sup.9-THC. One embodiment described herein relates to the transdermal administration of a .sup.9-THC prodrug for treating and preventing diseases and/or disorders.

The present invention relates to aromatic carbocycle or heterocycle compounds comprising an acid function and being of formula (5), ##STR00001##
wherein W, Q.sup.1, Q.sup.2, Q.sup.3, Q.sup.4, R.sup.1, R.sup.3, R.sup.4, R.sup.7, R.sup.9, R.sup.11, a, c, e, and g are as described in the description; and the use of such compounds in the treatment or the prevention of viral disorders, including HIV.

The present invention relates to aromatic carbocycle or heterocycle compounds comprising an acid function and being of formula (5), ##STR00001##
wherein W, Q.sup.1, Q.sup.2, Q.sup.3, Q.sup.4, R.sup.1, R.sup.3, R.sup.4, R.sup.7, R.sup.9, R.sup.11, a, c, e, and g are as described in the description; and the use of such compounds in the treatment or the prevention of viral disorders, including HIV.

An acid diffusion control agent includes a compound represented by a formula (1), a compound represented by a formula (2) or both thereof. R.sup.1 represents a hydrocarbon group comprising a monovalent alicyclic structure, or the like. R.sup.2 and R.sup.3 each independently represent a monovalent hydrocarbon group, or the like. R.sup.4 and R.sup.5 each independently represent a monovalent hydrocarbon group, or the like. R.sup.6 and R.sup.7 each independently represent a monovalent hydrocarbon group, or the like. R.sup.8 represents a monocyclic heterocyclic group together with the ester group and with the carbon atom. n is an integer of 1 to 6. R.sup.9 represents a monovalent hydrocarbon group, or the like. R.sup.10 represents a monovalent hydrocarbon group having 1 to 10 carbon atoms. R.sup.11 and R.sup.12 each independently represent a monovalent hydrocarbon group, or the like. R.sup.13 and R.sup.14 each independently represent a monovalent hydrocarbon group, or the like. ##STR00001##

An acid diffusion control agent includes a compound represented by a formula (1), a compound represented by a formula (2) or both thereof. R.sup.1 represents a hydrocarbon group comprising a monovalent alicyclic structure, or the like. R.sup.2 and R.sup.3 each independently represent a monovalent hydrocarbon group, or the like. R.sup.4 and R.sup.5 each independently represent a monovalent hydrocarbon group, or the like. R.sup.6 and R.sup.7 each independently represent a monovalent hydrocarbon group, or the like. R.sup.8 represents a monocyclic heterocyclic group together with the ester group and with the carbon atom. n is an integer of 1 to 6. R.sup.9 represents a monovalent hydrocarbon group, or the like. R.sup.10 represents a monovalent hydrocarbon group having 1 to 10 carbon atoms. R.sup.11 and R.sup.12 each independently represent a monovalent hydrocarbon group, or the like. R.sup.13 and R.sup.14 each independently represent a monovalent hydrocarbon group, or the like. ##STR00001##

Methods for producing hydrogenated cannabigerol and cannabichromene derivatives are disclosed. The methods preserve the aromatic olefins while selectively reducing the nonaromatic olefins using hydrogen gas, a hydrogen gas source, or a mixture thereof and a catalyst to produce the corresponding hydrogenated derivatives, in some aspects, the source of hydrogen gas comprises ammonium formate and/or formic acid. In some aspects, the catalyst is Pd/C or Pt/C.

Methods for producing hydrogenated cannabigerol and cannabichromene derivatives are disclosed. The methods preserve the aromatic olefins while selectively reducing the nonaromatic olefins using hydrogen gas, a hydrogen gas source, or a mixture thereof and a catalyst to produce the corresponding hydrogenated derivatives, in some aspects, the source of hydrogen gas comprises ammonium formate and/or formic acid. In some aspects, the catalyst is Pd/C or Pt/C.